Cuál es el precio por Scilex Holding Company (SCLX)

Precio por Scilex Holding Company (SCLX) es de$5.61

Cuál es la capitalización de mercado por Scilex Holding Company (SCLX)

Capitalización de mercado por Scilex Holding Company (SCLX) es $47.65M

Scilex Holding Company (SCLX) Ratio P/B

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Año	Ratio P/B	Cambiar
Not enough data for the provided dates.

Año

Ratio P/B

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/B	Diferencia del ratio P/B	País
Eli Lilly and Company LLY.US	31.0864	-	US
Johnson & Johnson JNJ.US	7.4766	-	US
AbbVie Inc. ABBV.US	-74.4354	-	US
Roche Holding AG RO.SW	8.4776	-	CH
Merck & Co., Inc. MRK.US	8.008	-	US

Empresa

Ratio P/B

Diferencia del ratio P/B

País